Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

  title={Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis},
  author={William J. Elliott and Peter M. Meyer},
  journal={The Lancet},

Comparative risk of new‐onset diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network meta‐analysis

According to the evidence, ARBs have an advantage over the other treatments in reducing the risk of NOD in elderly patients.

ACEIs/ARBs for the prevention of type 2 diabetes in patients with cardiovascular diseases: a systematic review and meta-analysis

A systematic review and meta-analysis found that ACEIs or ARBs can reduce the incidence of type 2 diabetes, especially in patients with hypertension, metabolic syndrome, pre-diabetes phase, congestive heart failure, or coronary heart disease, and is accordingly recommended as the first line antihypertensive agents in patientsWith cardiovascular diseases.

Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis

Based on the available evidence, there seems to be little or no difference between commonly used blood pressure lowering medications for primary prevention of cardiovascular disease.

Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis.

The cumulative evidence suggests that the use of ACEI/ARB prevents diabetes mellitus and may be of special clinical benefit in patients with hypertension and prediabetes or metabolic syndrome.

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis

The findings support the use of ACE inhibitors as the first line antihypertensive agent in patients with diabetes and calcium channel blockers might be the preferred treatment in combination with ACE inhibitors if adequate blood pressure control cannot be achieved by ACE inhibitors alone.

Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.

It is demonstrated that ACE inhibitors or ARBs should be preferred in patients with clinical conditions that may increase risk of NOD, since these drugs reduced NOD incidence and have favorable effects on CV and non-CV mortality in high CV risk patients.

Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial

In patients with CKD, all of the tested combination therapies demonstrated comparable efficacy in terms of prevention of cardiovascular events as well as maintenance of eGFR.

Comparative risk of new‐onset diabetes mellitus for antihypertensive drugs: A network meta‐analysis

New‐onset diabetes mellitus (NOD) refers to forms of diabetes mellitus that develop during the therapeutic processes of other diseases such as hypertension. This study has been conducted in a network

Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes

There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.



A systematic review of drug therapy to delay or prevent type 2 diabetes.

No single agent can be definitively recommended for diabetes prevention and future studies should be designed with diabetes incidence as the primary outcome and should be of sufficient duration to differentiate between genuine diabetes prevention as opposed to simple delay or masking of this condition.

Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.

Ramipril treatment was associated with a significantly lower risk of DM in African Americans with hypertensive kidney disease than amlodipine or metoprolol treatment.

Differential effects of antihypertensive drugs on new-onset diabetes?

  • W. Elliott
  • Medicine
    Current hypertension reports
  • 2005
Earlier studies indicated that most individuals who developed incident diabetes were "prediabetic" before beginning antihypertensive therapy, and ipso facto had increased cardiovascular risk compared with individuals with normal glucose tolerance, but data about incident diabetes are now available from 16 long-term, randomized, clinical trials of antihyertensive drugs.

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

New-onset diabetes could be strongly predicted by a newly developed risk score using baseline serum glucose concentration (non-fasting), body mass index, serum high-density lipoprotein cholesterol concentration, systolic blood pressure and history of prior use of antihypertensive drugs.

Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure

The angiotensin receptor blocker candesartan appears to prevent diabetes in heart failure patients, suggesting that the renin-angiotens in axis is implicated in glucose regulation.

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.

Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality and future trials should use low-doseDiuretics as the standard for clinically useful comparisons.

Antihypertensive therapy and incidence of type 2 diabetes: a systematic review.

The major antihypertensive classes may exert differential effects on diabetes incidence, although current data are far from conclusive, and ongoing placebo-controlled randomized trials involving potentially beneficial drug classes and examining diabetes incidence as a primary end point should provide more definitive evidence.

Antihypertensive Medications and the Risk of Incident Type 2 Diabetes

Thiazide diuretic and beta-blocker use were independently associated with a higher risk of incident diabetes and increased surveillance for diabetes in patients treated with these medications may be warranted.